Restoring O-glycosylation and expression of MUC2 limits progression of colorectal cancer

Yian Yang,Yuesong Yin,Wei Xu,Yan Kang,Jiawei Chen,Yanfeng Zou,Zhigang Xiao,Zheng Li,Peiguo Cao

DOI: https://doi.org/10.1101/2024.01.25.577208

2024-01-29

Abstract:This study investigated the molecular mechanisms underlying the regulation of MUC2 expression and O-glycosylation modification in colorectal cancer. In addition, the potential of rosiglitazone to inhibit colorectal cancer by improving MUC2 glycosylation to protect intestinal barrier function was explored. In vitro, lectin staining combined with Co-IP assay was used to detect glycosyltransferases regulating MUC2 O-glycosylation. ChIP and Luciferase experiments were used to verify the transcription factors regulating MUC2 expression level. Samples from CRC patients were used to detect differences in multimolecular expression. The AOM/DSS mouse model was used to validate the effect of rosiglitazone on inhibiting colorectal cancer progression. Our results showed that B3GNT6 acts as a glycosyltransferase to enhance the O-glycosylation level of MUC2 and maintain protein stability to resist degradation by StcE secreting from pathogenic bacteria. Furthermore, KLF4 directly promotes the transcription of B3GNT6 and MUC2, which are regulated by PPARg. Rosiglitazone activated PPARg-KLF4-B3GNT6 axis which increased the expression level and glycosylation of MUC2 and further improved the intestinal mucosal barrier function to delay the development of colorectal cancer in mice. These data suggest that O-glycosylation and expression of MUC2 is key to the maintenance of functional intestinal mucosa and rosiglitazone is a potential colorectal cancer therapeutic agent.

Cancer Biology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore whether restoring the O-glycosylation modification and expression levels of the MUC2 protein can limit the development of Colorectal Cancer (CRC). Specifically, the researchers focus on the following aspects:

1. **Regulatory Mechanisms of MUC2 Expression and O-Glycosylation Modification in Colorectal Cancer**:
- Researchers investigated the regulatory mechanisms of MUC2's O-glycosylation modification and expression levels through various experimental methods (such as lectin staining, Co-IP, ChIP, and luciferase assays).
- They found that B3GNT6, as a glycosyltransferase, can enhance the O-glycosylation level of MUC2, thereby maintaining its protein stability and resisting degradation caused by the pathogen-secreted StcE.

2. **Inhibitory Effect of PPARγ Agonist Rosiglitazone on Colorectal Cancer**:
- Researchers further explored whether the PPARγ agonist Rosiglitazone can protect intestinal barrier function by improving MUC2 glycosylation modification, thereby inhibiting the development of colorectal cancer.
- Through in vitro experiments and the AOM/DSS mouse model, they verified the mechanism of action of Rosiglitazone, which is to increase MUC2 expression and glycosylation levels by activating the PPARγ-KLF4-B3GNT6 axis, thereby improving intestinal mucosal barrier function and delaying the development of colorectal cancer.

3. **Potential Therapeutic Strategies**:
- This study reveals the importance of MUC2's O-glycosylation modification and expression levels in maintaining a functional intestinal mucosa and proposes the potential of Rosiglitazone as a therapeutic drug for colorectal cancer.

### Summary

This paper provides new insights and potential therapeutic strategies for the treatment of colorectal cancer by deeply exploring the regulatory mechanisms of MUC2's O-glycosylation modification and expression levels in colorectal cancer, as well as the role of the PPARγ agonist Rosiglitazone. The research results suggest that restoring the O-glycosylation modification and expression levels of MUC2 may become an effective treatment method for colorectal cancer.